Global Cancer Biologics Market Projected to Reach $189 Billion by 2035, Driven by Antibody Dominance and Precision Medicine
核心洞察
The global cancer (搜索) biologics market is forecast to grow from $169 billion to $189 billion by 2035, reflecting a compound annual growth rate of 8.9%.
Antibodies are expected to account for approximately 70% of the total market share by 2035, underscoring their specificity in targeting cancer (搜索) cells.
North America currently dominates with a 45% revenue share, while the Asia-Pacific region shows higher growth potential.
The global cancer (搜索) biologics market is poised for substantial expansion, with projections indicating growth from $169 billion in the current year to $189 billion by 2035, according to a new report from ResearchAndMarkets.com (搜索). This trajectory represents a compound annual growth rate (CAGR) of 8.9% over the forecast period, reflecting the increasing centrality of biologic therapies in oncology treatment paradigms.
Cancer (搜索) ranks as the third most common cause of death globally, and biologic therapies have emerged as a cornerstone of modern oncologic care. Biologics now represent nearly 70% of the market for cancer therapeutics, a dominance exemplified by the commercial success of agents such as KEYTRUDA and Darzalex. The report segments the market across multiple parameters, including type of biologic, target indication, and geography.
Antibodies Maintain Dominance, Emerging Modalities Gain Traction
Among biologic types, antibodies are predicted to account for 70% of the total market share by 2035, highlighting their established specificity in targeting cancer (搜索) cells. The broader market segmentation encompasses antibodies, cell and gene therapies, oncolytic viral therapies, mRNA therapies and vaccines, nucleotide-based drugs, peptides, and other biologics.
The report identifies mRNA therapies and vaccines as a segment with notable growth potential for future cancer (搜索) treatment. Technological advancements in next-generation sequencing and CRISPR-Cas9 gene editing have significantly propelled the market through precise targeting and personalized treatment approaches.
Blood Cancer (搜索) Leads Indication Segments
Blood cancer (搜索) holds the largest market share among target indications, a position attributed to improved survival rates achieved through targeted treatments. The comprehensive indication analysis spans 15 cancer types, including lung cancer, colorectal cancer, breast cancer, prostate cancer, skin cancer, renal cancer, cervical and gastric cancer, liver cancer, bladder cancer, ovarian cancer, pancreatic cancer, head and neck cancer, and brain cancer.
The bladder cancer (搜索) segment is specifically noted as demanding drugs that deliver better progression-free survival, with urothelial cancer representing a strong presence within bladder cancer cases. The breast cancer sector is highlighted for prominent growth driven by targeted therapy development.
Regional Dynamics: North America Leads, Asia-Pacific Accelerates
North America dominates the global cancer (搜索) biologics market with a 45% revenue share, driven by advancements in healthcare infrastructure and supportive regulatory frameworks. The United States represents the largest single-country market within the region.
The Asia-Pacific region demonstrates higher growth potential, with country-level analyses covering India, Japan, South Korea, and China. Europe maintains a significant presence, with detailed market assessments for Germany, France, the UK, Italy, Spain, and the rest of Europe.
Market Drivers and Challenges
Several factors are propelling market expansion, including the rising incidence of cancer (搜索) globally, expanding pipelines for gene therapies, and increased R&D investments. The growing focus on personalized cancer biologic therapies continues to attract pharmaceutical companies seeking to innovate and address unmet patient needs. The report also notes the introduction of tailored dosing strategies aimed at preventing under- or overdosing, alongside an increasing emphasis on patient-reported outcomes in clinical trials.
Despite robust growth, the market faces significant headwinds. High development costs, regulatory barriers, supply chain complexities, and competition from biosimilars present ongoing challenges to consistent growth. The competitive landscape features major pharmaceutical players including AbbVie (搜索), Amgen, AstraZeneca, BioNTech, Bristol Myers Squibb (搜索), Eli Lilly and Company, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck (搜索), Novartis, Pfizer, Roche, Sanofi, and Takeda Pharmaceuticals (搜索).